Sulfonamide compounds and uses as tnap inhibitors

A compound of Formula I, or a pharmaceutically acceptable salt, polymorph, solvate, tautomer, metabolite, or N-oxide thereof:

• wherein:
• Y1 and Y2 are independently a bond or —N(R6)—, wherein at least one of Y1 and Y2 is —N(R6)—;
• L1 and L2 are independently a bond or optionally substituted alkylene;
• X1 is ═N— or ═C(R2)—;
• X2 is ═N— or ═C(R3)—;
• R1 and R4 are independently selected from the group consisting of hydrogen, halogen, —CN, —C(O)—N(R7)—R8, —C(O)—O—R9, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted alkoxy, haloalkyl, haloalkoxy, optionally substituted phenyl, and optionally substituted 5- or 6-membered heteroaryl;
• R2, R3, and R5 are independently selected from the group consisting of hydrogen, halogen, —CN, —C(O)—N(R7)—R8, —C(O)—O—R9, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted alkoxy, haloalkyl, haloalkoxy, optionally substituted phenyl, and optionally substituted 5- or 6-membered heteroaryl;
• R6 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl;
• R7 and R8 are independently hydrogen, optionally substituted alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted phenyl, or R7 and R8 together with the nitrogen atom to which they are attached form an optionally substituted heterocycloamino;
• R9 is selected from the group consisting of hydrogen, optionally substituted alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, and optionally substituted phenyl;
• and
• A is selected from the group consisting of —C(O)—N(R7)—R8, —C(O)—O—R9, optionally substituted phenyl, and optionally substituted 5- or 6-membered heteroaryl.